A phase 3 randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer
A study of weekly chemotherapy and bevacizumab in advanced ovarian cancer
What is this study about?
ICON8B is investigating the combination of dose-dense chemotherapy and targeted anti-angiogenic therapy (bevacizumab) in a sub-group of women with high-risk stage III-IV ovarian cancer to see if it is superior to either strategy alone. High-risk is defined as women with FIGO (2013) stage IIIA1(ii), stage IIIA2 with positive retroperitoneal lymph nodes >1cm in diameter, stage IIIB or IIIC disease with >1cm residual disease following immediate primary surgery (IPS) or those receiving primary chemotherapy with or without delayed primary surgery (DPS), and all stage IV disease.
Type of study
Who is funding the study?
Cancer Research UK.
When is it taking place?
The trial opened to recruitment 21st July 2015
Where is it taking place?
UK mainland, Ireland, and Switzerland
Who is included?
Patients with newly diagnosed, histologically confirmed, high-risk ovarian cancer with no contraindications to receiving bevacizumab.